Tonix Pharmaceuticals Holding Corp. announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA. Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA's proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism.
The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to the long-acting metabolite norcyclobenzaprine, supporting durable analgesic benefits with improved tolerability. TONMYA represents the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years, addressing a chronic pain condition that affects millions of adults.
For business and technology leaders in healthcare, this development demonstrates how pharmaceutical innovation continues to advance through targeted delivery systems. The pharmacokinetic optimization achieved through TONMYA's sublingual administration represents a significant advancement in pain management therapeutics, potentially offering a non-opioid alternative with improved safety profiles.
The publication of this data in a peer-reviewed journal provides scientific validation for the drug's mechanism of action, which could influence prescribing patterns and insurance coverage decisions. For investors and industry observers, the research supports Tonix's broader development strategy across multiple therapeutic areas. The company's development portfolio includes candidates for central nervous system disorders, immunology, immuno-oncology, rare disease and infectious disease.
Notably, TNX-102 SL is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense. The company also has immunology development candidates including TNX-1500, a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and treatment of autoimmune diseases.
For the broader biotechnology sector, Tonix's integrated approach combining commercial products with a diversified pipeline demonstrates a sustainable business model in the competitive pharmaceutical landscape. The company's infectious disease research facility in Frederick, Md., and its contract with the U.S. DoD's Defense Threat Reduction Agency for up to $34 million over five years for TNX-4200 development further positions the company at the intersection of commercial healthcare and national security priorities.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. BioMedWire, which distributed the original announcement, is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers various communication solutions. For more information, please visit https://www.BioMedWire.com.
